ArticleReviews in cardiovascular medicine2023
The Clinical Diagnosis and Management of Long QT Syndrome: Insights from the 2022 ESC Guidelines.
Article in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Modeling ventricular tachycardia in genetic long QT syndrome using engineered cardiac tissues.Bioactive materials · 2026Article
- Long QT Syndrome Type 5 With Coexisting KCNE1 and RYR2 Variants: A Diagnostic Ambiguity.Clinical case reports · 2026Article
- Article
- Congenital Long QT Syndrome: A Focus on Risk Stratification and Management.Reviews in cardiovascular medicine · 2025Review
- WhenFrontiers in pharmacology · 2025Article
- Management of Long QT Syndrome: A Systematic Review.Cureus · 2024Review
- Just as the girl communicating with her mother using sign language: an electrocardiogram can convey a lot through its signals.European heart journal. Case reports · 2024Article
- A novel clinical perspective on subarachnoid hemorrhage complicated by myocardial injury: independent predictors and short-term prognostic assessment.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long QT syndrome (LQTS) is an uncommon disorder that is characterized by QT prolongation and torsade de pointes leading to sudden cardiac death. It is mainly triggered by adrenergic activation. Since LQTS is rare, it is often underdiagnosed. The updated 2022 European Society of Cardiology (ESC) guidelines aim to define the diagnosis of LQTS and spread its management. However, some unknowns and uncertainties still exist regarding the treatment of LQTS. This commentary is geared to the expansion of clinical applications of drug therapies for different subtypes of LQTS based on the 2022 ESC guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.